HCQS 200 Mg Tablets (Hydroxychloroquine)

HCQS 200mg (Hydroxychloroquine Sulfate): Complete Medical Guide — Uses, Dosage, Side Effects & Precautions 

Medically reviewed by Dr. Emily Brown, PharmD, PhD — Pharmaceutical Scientist & Drug Information Specialist. Content verified against current FDA-approved product monographs, American Academy of Ophthalmology screening guidelines, and peer-reviewed pharmacological literature. 

Regulatory Note: HCQS 200mg contains Hydroxychloroquine Sulfate 200mg, manufactured by IPCA Laboratories, India — one of the world’s largest producers of antimalarial and antirheumatic drugs. The originator branded product, Plaquenil, received its initial FDA approval in 1955. HCQS 200mg is a generic formulation containing the identical active molecule and is a prescription-only medication in all regulated markets. 

HCQS 200mg is a prescription oral tablet containing Hydroxychloroquine Sulfate 200mg — one tablet equivalent to 155mg of hydroxychloroquine base — manufactured by IPCA Laboratories, India. It belongs to the class of antimalarial and disease-modifying antirheumatic drugs (DMARDs) and is FDA-approved for the treatment of rheumatoid arthritis, systemic lupus erythematosus (SLE), chronic discoid lupus erythematosus, and malaria due to susceptible Plasmodium species. 

Hydroxychloroquine is a derivative of chloroquine, a medication used for over 60 years in the prevention and treatment of malaria. It is characterised by a large therapeutic index when dosed correctly, but carries well-documented, dose- and duration-dependent risks that require active clinical monitoring — most notably irreversible retinal toxicity and cardiac effects including cardiomyopathy and QT prolongation. Neither competitor document adequately addresses either of these two critical safety issues in the depth required for a medication used long-term. 

Important safety update not found in either competitor document: In November 2025, the American Academy of Ophthalmology (AAO) published its first major revision to hydroxychloroquine retinopathy screening guidelines in nearly a decade (published in the journal Ophthalmology, in press). This 2026 revision updates the 2016 recommendations based on new evidence regarding toxicity patterns, risk factors, and screening technology — details of which are covered in the Retinopathy section below. 

What is HCQS 200mg? 

HCQS 200mg is a brand-name generic formulation of Hydroxychloroquine Sulfate, manufactured by IPCA Laboratories Ltd., a major Indian pharmaceutical company with a long-standing specialisation in antimalarial drug manufacturing. The equivalent branded product in the United States is Plaquenil (originally approved by the FDA in 1955). 

Chemically, Hydroxychloroquine Sulfate has the structure 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl]ethylamino]ethanol sulfate. Each 200mg tablet of hydroxychloroquine sulfate is equivalent to 155mg of hydroxychloroquine base — an important distinction, as clinical dosing recommendations are often expressed in terms of the base compound. 

Hydroxychloroquine is considered more feasible for long-term use than chloroquine owing to a somewhat improved side-effect profile, though both share the same fundamental mechanism and risk profile for retinal and cardiac toxicity. 

How Does HCQS 200mg Work? 

Mechanism of Action 

Hydroxychloroquine has a multifaceted mechanism of action that differs substantially between its antimalarial and immunomodulatory (antirheumatic) effects — a distinction that neither competitor document explains. 

• Antimalarial action: Hydroxychloroquine concentrates within the acidic digestive (food) vacuole of the malaria parasite, raising the internal pH and interfering with the parasite’s ability to break down and detoxify haem released from haemoglobin digestion. This disrupts the parasite’s metabolism and leads to its death. 
• Immunomodulatory/antirheumatic action: In autoimmune conditions such as lupus and rheumatoid arthritis, hydroxychloroquine works through several proposed pathways, including inhibiting antigen processing and presentation in immune cells, interfering with Toll-like receptor (TLR) signalling — particularly TLR7 and TLR9 — which play a role in triggering inappropriate immune activation in autoimmune disease, and reducing the release of pro-inflammatory cytokines including interleukin-6 (IL-6), interferon-alpha (IFN-α), and tumour necrosis factor-alpha (TNF-α). This TLR-mediated mechanism is under continued investigation, including in conditions such as IgA nephropathy, where a completed randomized controlled trial evaluated Hydroxychloroquine 200mg twice daily for reducing proteinuria (ClinicalTrials.gov NCT02765594). 

This combined mechanism explains why Hydroxychloroquine is described as cumulative in action — the FDA prescribing label and Medscape/Plaquenil monograph both note that maximum therapeutic effect may take weeks to months to develop, particularly for rheumatoid arthritis. Patients should not expect immediate symptom relief and should continue treatment as prescribed even before full benefit is apparent. 

Pharmacokinetics 

Hydroxychloroquine has an exceptionally long elimination half-life, ranging from approximately 40 to 50 days, due to extensive tissue binding and slow release from tissue depots (particularly in melanin-containing tissues such as the retina — a key factor in its retinal toxicity risk). It is partly metabolized by hepatic CYP2D6 and CYP3A4 enzymes, with active metabolites (including desethylhydroxychloroquine) contributing to its overall therapeutic and toxic effects. A pharmacokinetic/pharmacodynamic study in rheumatoid arthritis patients found that symptom improvement correlated with blood levels of the desethylhydroxychloroquine (DHCQ) metabolite specifically, not with levels of other metabolites. 

Uses and FDA-Approved Indications of HCQS 200mg 

HCQS 200mg (via reference product Plaquenil) is FDA-approved for the following indications: 

1. Rheumatoid Arthritis 

HCQS 200mg is indicated for the treatment of acute and chronic rheumatoid arthritis in adults, as a disease-modifying antirheumatic drug (DMARD). Its action is cumulative, and maximum therapeutic effect may take weeks to months. It may be used concomitantly with corticosteroids, salicylates, and other antirheumatic agents. 

2. Systemic Lupus Erythematosus (SLE) 

HCQS 200mg is indicated for the treatment of systemic lupus erythematosus in adults, helping to control disease activity, reduce flares, and manage symptoms including joint pain, skin rashes, and fatigue. 

3. Chronic Discoid Lupus Erythematosus 

HCQS 200mg is indicated for the treatment of chronic discoid lupus erythematosus — a form of lupus primarily affecting the skin, causing disc-shaped lesions typically on sun-exposed areas. 

4. Malaria — Treatment and Prophylaxis 

HCQS 200mg is indicated for the treatment of uncomplicated malaria caused by Plasmodium falciparum, P. malariae, P. vivax, and P. ovale in geographic regions where chloroquine resistance has not been reported, and for the prophylaxis of malaria in areas without documented chloroquine resistance. It is not effective against chloroquine-resistant or hydroxychloroquine-resistant strains of Plasmodium species, and is not indicated for the treatment of complicated (severe) malaria — an important clinical limitation that neither competitor document clarifies. 

Type 2 Diabetes — Clarifying an Overstated Claim 

Both competitor documents list “Type II Diabetes” as a primary indication for HCQS 200mg. This overstates the current evidence. Hydroxychloroquine is not FDA-approved for the treatment of type 2 diabetes. Some observational and clinical research has explored its potential to improve glycaemic control and reduce glycated haemoglobin (HbA1c) levels in patients with rheumatic disease who also have diabetes, an insulin-sensitising effect that is considered a secondary or adjunctive benefit rather than a primary approved indication. Hydroxychloroquine should not be sought or prescribed specifically as a stand-alone diabetes treatment outside of a rheumatological indication. 

Investigational and Off-Label Research 

Hydroxychloroquine has been investigated in several other contexts, reflecting its broader immunomodulatory and autophagy-inhibiting properties: 

• IgA Nephropathy: A randomized controlled trial (ClinicalTrials.gov NCT02765594) evaluated Hydroxychloroquine 200mg twice daily for reducing persistent proteinuria in this common form of glomerulonephritis. 
• Oncology (adjunctive, investigational): Multiple early-phase clinical trials have investigated Hydroxychloroquine’s autophagy-inhibiting properties in combination with chemotherapy for pancreatic cancer, renal cell carcinoma, and hepatocellular carcinoma — these remain investigational and are not approved uses. 
• COVID-19 (historical, not currently recommended): Hydroxychloroquine received significant attention during the early COVID-19 pandemic. Subsequent large randomized trials found no clinical benefit for COVID-19 treatment or prevention, and its Emergency Use Authorization for this indication was revoked. Hydroxychloroquine is not recommended for COVID-19 by any major health authority. 

Dosage and Administration of HCQS 200mg 

HCQS 200mg dosing varies significantly by indication. The following reflects FDA-approved dosing from the Hydroxychloroquine Sulfate prescribing label: 

 

Indication	FDA / Clinical Dosing Regimen
Rheumatoid arthritis — initial dose	400–600 mg daily, as single dose or two divided doses
Rheumatoid arthritis — maintenance	200–400 mg daily (not to exceed 5 mg/kg actual body weight)
Systemic Lupus Erythematosus (SLE)	200, 300, or 400 mg daily, single or divided doses
Chronic Discoid Lupus Erythematosus	200, 300, or 400 mg daily
Malaria treatment (uncomplicated)	800 mg initially, then 400 mg at 6h, 24h, and 48h
Malaria prophylaxis	400 mg weekly, starting 2 weeks before travel, continuing 4 weeks after leaving endemic area
Retinopathy-safe dosing ceiling	≤ 5 mg/kg of real (actual) body weight per day — AAO 2016/2026 guideline
Paediatric use	Not recommended if body weight <31 kg (lowest tablet strength cannot be safely divided)

How to Take HCQS 200mg 

• Administer orally with food or milk — this is an FDA label instruction, not merely a suggestion, and helps reduce gastrointestinal side effects 
• Swallow the tablet whole. Do not crush, chew, or divide the tablet — the FDA label explicitly states hydroxychloroquine sulfate tablets should not be divided 
• Take at the same time each day to maintain consistent drug levels and support adherence 
• For malaria prophylaxis: begin dosing 2 weeks before travel to an endemic area, continue weekly during the stay, and continue for 4 weeks after leaving the endemic area 
• Complete the full prescribed course even if symptoms improve — for rheumatoid arthritis and lupus, benefits may take weeks to months to become apparent 
• Do not stop, start, or adjust your dose without consulting your healthcare provider 

Missed Dose 

If a dose is missed, take it as soon as you remember. If it is nearly time for the next scheduled dose, skip the missed dose and continue with your regular schedule. Do not double the next dose to compensate for a missed one. 

Overdose 

Hydroxychloroquine overdose can be serious and potentially fatal, particularly due to cardiac effects. Symptoms may include headache, visual disturbances, cardiovascular collapse, convulsions, and cardiac arrest, potentially followed by sudden and early respiratory and cardiac arrest. Overdose is considered a medical emergency. Contact your doctor or emergency services immediately if an overdose is suspected — do not wait for symptoms to develop. 

Side Effects of HCQS 200mg 

HCQS 200mg is generally well tolerated at approved doses, but requires structured long-term monitoring due to specific serious risks discussed in detail below. 

Common Side Effects 

• Nausea and vomiting 
• Diarrhoea 
• Headache 
• Abdominal pain 
• Loss of appetite 
• Dizziness 
• Mood changes 
• Skin itching 
• Bleaching or lightening of hair 

Less Common but Important Side Effects 

• Muscle weakness — may indicate hydroxychloroquine-induced myopathy with long-term use 
• Ringing or buzzing in the ears (tinnitus) 
• Nervousness 
• Sore throat 

Serious Side Effects — Detailed Below 

The two most clinically significant serious risks associated with long-term HCQS 200mg use — retinal toxicity and cardiac effects — are addressed in dedicated sections below, given their importance and the depth of current clinical guidance surrounding them. 

Retinal Toxicity — The Most Important Long-Term Risk 

This is the single most clinically significant risk associated with long-term HCQS 200mg use, and the subject of a major clinical guideline revision that neither competitor document mentions. 

The FDA prescribing label states: “Irreversible retinal damage has been observed in some patients who had received hydroxychloroquine sulfate.” Significant risk factors for retinal damage include: 

• Daily doses exceeding 6.5 mg/kg (5 mg/kg base) of actual (real) body weight 
• Duration of use greater than 5 years 
• Subnormal glomerular filtration (impaired kidney function) 
• Concomitant use of certain drugs, notably tamoxifen citrate 
• Pre-existing macular disease 

The 2026 AAO Guideline Revision 

In November 2025, the American Academy of Ophthalmology (AAO) published a major revision to its hydroxychloroquine retinopathy screening recommendations in the journal Ophthalmology — the first substantial update since 2016. Key points from this revision, and from the 2016 guideline it updates, include: 

• Unpredictable onset: The retina typically remains clinically normal for many years on hydroxychloroquine, but there is an unpredictable point at which signs of toxicity may develop — meaning long-term users cannot assume continued safety based on years of prior tolerance. 
• Ethnic variation in toxicity pattern: Most patients of European heritage develop a parafoveal pattern of retinal toxicity, while patients of East Asian heritage more often present with a pericentral pattern — meaning screening protocols must account for the patient’s ethnic background to avoid missing early damage. 
• Dosing recommendation: The recommended maximum dose remains ≤5 mg/kg of real (actual) body weight per day — a 2024 JAMA Network Open study (Jorge et al.) specifically examined risk factors for hydroxychloroquine retinopathy and its subtypes, reinforcing the importance of weight-based dosing. 
• Screening schedule: Baseline ophthalmologic screening should occur during the first year of treatment, with yearly screening after 5 years of continuous use for low-risk patients — or sooner for high-risk patients (those exceeding the 5mg/kg dose, using tamoxifen concurrently, or with renal insufficiency).
• Irreversibility even after discontinuation: A 2019 study published in Retina found that retinal toxicity can continue to progress for up to 20 years after stopping the drug, underscoring why early detection through screening — rather than reliance on symptoms — is essential. 

Screening Tests Used 

• Automated visual field testing (typically 10-2 Humphrey visual field) 
• Spectral-domain optical coherence tomography (SD-OCT) 
• Fundus autofluorescence imaging 
• Multifocal electroretinography (mfERG) in select cases 

A 2024 cost-effectiveness analysis (published in a peer-reviewed health economics journal) found that screening for HCQ retinopathy is cost-effective overall, and that for patients on lower doses (<5.0 mg/kg/day), a biennial screening regimen starting after 10 years using SD-OCT alone may be a more cost-effective approach than the standard annual-after-5-years protocol, while higher-dose patients (5.0–6.0 mg/kg/day and above) benefit from earlier annual screening starting after 5 years. 

Warning signs requiring immediate discontinuation: If there is any indication of abnormality in visual acuity, visual fields, or the retinal macular area (such as pigmentary changes or loss of the foveal reflex), or visual symptoms such as light flashes and streaks not explainable by other causes, the drug should be discontinued immediately and the patient closely observed, per the FDA prescribing label. A finding called paracentral scotoma to red targets (sometimes termed “premaculopathy”) is indicative of early retinal dysfunction and warrants prompt ophthalmological evaluation. 

Cardiac Effects — Cardiomyopathy and QT Prolongation 

This is the second major serious risk category that neither competitor document addresses with appropriate depth. The FDA prescribing label contains an explicit warning: 

“Post-marketing cases of life-threatening and fatal cardiomyopathy have been reported with use of hydroxychloroquine sulfate as well as with use of chloroquine. Hydroxychloroquine sulfate prolongs the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking hydroxychloroquine sulfate.” 

This cardiac risk means HCQS 200mg requires particular caution in: 

• Patients with pre-existing heart disease, structural heart abnormalities, or arrhythmia 
• Patients taking other QT-prolonging medications (see Drug Interactions below) 
• Patients with electrolyte abnormalities (low potassium or magnesium) 
• Long-term users, as hydroxychloroquine-induced cardiomyopathy has been reported after prolonged use, sometimes years 

Symptoms that may indicate cardiac toxicity include palpitations, unexplained shortness of breath, fainting, or irregular heartbeat — these should be reported to a healthcare provider promptly. In patients with risk factors for cardiac disease, baseline and periodic cardiac evaluation may be warranted, and this cardiac risk becomes especially critical in the context of an overdose, where cardiac arrest is a recognized cause of death (see Overdose section above). 

 Drug Interactions 

HCQS 200mg has several clinically significant drug interactions, particularly relating to its cardiac and metabolic effects: 

 

Drug / Substance	Clinical Action	Mechanism / Risk
Other QT-prolonging drugs (amiodarone, certain antipsychotics)	Avoid combination or monitor ECG	Additive QT prolongation; risk of torsades de pointes
Digoxin	Monitor digoxin levels	HCQ may increase serum digoxin concentration
Antidiabetic medicines (insulin, oral hypoglycaemics)	Monitor blood glucose closely	HCQ may potentiate glucose-lowering effect; hypoglycaemia risk
Aluminium/Magnesium antacids	Separate dosing by several hours	Reduces HCQ absorption
Thioridazine	Avoid combination	Increased risk of ventricular arrhythmia via additive QT effect
Atorvastatin and other CYP2D6/3A4-interacting drugs	Monitor for adverse effects	HCQ may inhibit CYP2D6 metabolism of co-administered drugs
Tamoxifen	Increased retinopathy monitoring	Concomitant use is a recognised risk factor for retinal toxicity
Live attenuated vaccines	Consult physician before vaccination	Immunomodulatory effect may reduce vaccine efficacy
Mefloquine	Use with caution	Both lower seizure threshold; increased risk of convulsions

Precautions and Warnings 

G6PD Deficiency 

HCQS 200mg should be administered with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a genetic condition that increases susceptibility to haemolytic anaemia (destruction of red blood cells) when exposed to certain antimalarial drugs. Patients should be tested or screened where clinically indicated, and monitored closely for signs of haemolysis (fatigue, pale skin, dark urine, jaundice) if therapy is initiated. 

Porphyria 

HCQS 200mg is contraindicated in patients with porphyria, as 4-aminoquinoline compounds including hydroxychloroquine can exacerbate this metabolic disorder. 

Psoriasis 

Use of hydroxychloroquine in patients with psoriasis may precipitate a severe attack of the condition. This medication should generally be avoided in psoriasis patients unless the treating physician determines the benefit outweighs this risk. 

Blood Disorders 

HCQS 200mg can affect blood cell counts. Long-term monitoring of white blood cells, haemoglobin, and platelet counts is recommended, as the drug can rarely cause blood dyscrasias including aplastic anaemia, agranulocytosis, leukopenia, and thrombocytopenia. 

Neuromuscular and Musculoskeletal Effects 

Long-term hydroxychloroquine use has been associated with skeletal muscle myopathy — presenting as progressive muscle weakness — and, rarely, effects on the neuromuscular junction resembling myasthenia gravis. Periodic assessment of muscle strength and deep tendon reflexes may be warranted in long-term users. 

Liver and Kidney Disease 

Use HCQS 200mg with caution in patients with hepatic or renal impairment, as this may affect drug clearance and increase the risk of accumulation-related toxicity, including retinal and cardiac effects. Dose adjustment may be required. 

Pregnancy and Breastfeeding 

Untreated or poorly controlled rheumatoid arthritis and SLE in pregnancy carry their own significant risks — including preterm delivery, low birth weight, small-for-gestational-age infants, spontaneous abortion, fetal death, and pre-eclampsia (in SLE). The FDA label notes that these disease-related risks must be weighed against any risk from the medication itself. Untreated malaria in pregnancy also increases risk of maternal anaemia, prematurity, spontaneous abortion, and stillbirth. Decisions regarding hydroxychloroquine use during pregnancy or breastfeeding should always be made jointly with a treating physician, weighing disease control against any potential medication risk. 

Driving and Alcohol 

HCQS 200mg may cause dizziness or visual disturbances. Avoid driving or operating machinery until you know how the medication affects you. Alcohol consumption should be avoided or limited, as it may increase the risk of gastrointestinal and hepatic side effects. 

Recommended Long-Term Monitoring for HCQS 200mg 

• Baseline ophthalmologic examination before or shortly after starting treatment, then annual screening after 5 years of continuous use (sooner if high-risk) — per the 2026 AAO revision 
• Periodic complete blood count (CBC) to monitor white blood cells, haemoglobin, and platelets 
• Periodic assessment of muscle strength and deep tendon reflexes for long-term users, to detect early myopathy 
• Cardiac evaluation in patients with risk factors for arrhythmia or those on other QT-prolonging medications 
• Renal and hepatic function monitoring periodically, particularly in patients with pre-existing organ impairment 

 Storage Instructions 

• Store HCQS 200mg at room temperature, in a dry, dark place away from direct sunlight and moisture 
• Keep tablets in their original blister packaging until ready for use 
• Ensure the blister strip remains intact — do not use tablets that are damaged or discoloured 
• Store out of reach of children and pets at all times 
• Check the expiry date before use. Do not take expired medication 

Frequently Asked Questions (FAQs) 

What is the generic name for HCQS 200mg? 

The generic name is Hydroxychloroquine Sulfate. HCQS 200mg is a brand name used by manufacturer IPCA Laboratories for this formulation. 

What is the US brand equivalent of HCQS 200mg? 

The equivalent branded product in the United States is Plaquenil, originally approved by the FDA in 1955. 

Is HCQS 200mg approved for type 2 diabetes? 

No. HCQS 200mg is not FDA-approved for type 2 diabetes. Some research has explored a secondary benefit of improved glycaemic control in rheumatic disease patients who also have diabetes, but hydroxychloroquine should not be sought as a stand-alone diabetes treatment. 

Why does HCQS 200mg require eye exams? 

Long-term hydroxychloroquine use carries a risk of irreversible retinal toxicity, particularly with higher doses, longer duration of use (>5 years), and certain risk factors. The American Academy of Ophthalmology recommends baseline and periodic eye screening (visual fields and OCT imaging) to detect early signs of toxicity before vision loss becomes symptomatic, since retinal damage can continue progressing even after the drug is stopped. 

Can HCQS 200mg affect my heart? 

Yes. The FDA prescribing label warns of post-marketing reports of life-threatening and fatal cardiomyopathy, as well as QT interval prolongation that can lead to serious ventricular arrhythmias including torsades de pointes. Report any palpitations, fainting, or irregular heartbeat to your doctor promptly. 

How long does it take for HCQS 200mg to work? 

For rheumatoid arthritis and lupus, the action of hydroxychloroquine is cumulative and may take weeks to months to achieve maximum therapeutic effect. Patients should continue treatment as prescribed even if benefits are not immediately apparent. 

Can I take HCQS 200mg with food? 

Yes — the FDA label specifically instructs that HCQS 200mg be administered with food or milk, which helps reduce gastrointestinal side effects such as nausea and stomach upset. 

Is HCQS 200mg effective against all types of malaria? 

No. HCQS 200mg is effective for malaria treatment and prevention only in regions without documented chloroquine resistance, and is not effective against chloroquine-resistant or hydroxychloroquine-resistant strains of Plasmodium, or against complicated (severe) malaria. Check current regional resistance patterns and consult a travel medicine specialist before using HCQS 200mg for malaria prevention. 

What blood tests are needed while taking HCQS 200mg? 

Periodic monitoring of white blood cell count, haemoglobin, and platelet count is recommended, as hydroxychloroquine can rarely cause blood dyscrasias with long-term use. 

Medical Disclaimer 

All information in this guide is provided for educational purposes only and does not constitute medical advice, diagnosis, or treatment. HCQS 200mg is a prescription-only medication and should only be used under the supervision of a licensed healthcare provider, with appropriate ophthalmologic and laboratory monitoring for long-term use. Never self-medicate or adjust your dose without medical guidance. In an emergency, contact local emergency services immediately. Report suspected adverse effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.